

Biallelic variants for autism....

1 **Autism spectrum disorder trios from consanguineous populations are enriched**
2 **for rare biallelic variants, identifying 32 new candidate genes**

3 **Running title:** Biallelic variants for autism and consanguinity

4

5 Ricardo Harripaul^{1,2§}, Ansa Rabia^{1,3,4§}, Nasim Vasli¹, Anna Mikhailov¹, Ashlyn Rodrigues¹,
6 Stephen F. Pastore¹, Tahir Muhammad^{1,2}, Thulasi Thiruvallur Madanagopal¹, Aisha Nasir
7 Hashmi¹, Clinton Tran¹, Cassandra Stan¹, Katherine Aw¹, Clement Zai¹, Maleeha Azam⁵, Saqib
8 Mahmood³, Abolfazl Heidari⁶, Raheel Qamar^{5,7}, Leon French^{2,8}, Shreejoy Tripathy^{2,8}, Zehra
9 Agha^{5,9}, Muhammad Iqbal¹⁰, Majid Ghadami¹¹, Susan L. Santangelo^{12,13,14}, Bita Bozorgmehr¹,
10 Laila Al Ayadhi¹⁵, Roksana Sasanfar¹⁶, Shazia Maqbool¹⁷, James A. Knowles¹⁸, Muhammad
11 Ayub^{19,20*}, John B Vincent^{1,2,21*}

12

13 ¹Molecular Neuropsychiatry & Development (MiND) Lab, Campbell Family Mental Health

14 Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada;

15 ²Institute of Medical Science, University of Toronto, Toronto, ON, Canada;

16 ³University of Health Sciences, & NUR International University, Lahore, Pakistan;

17 ⁴CMH Lahore Medical College & Institute of Dentistry, Lahore (affiliated with National

18 University of Medical Sciences, Rawalpindi), Pakistan;

19 ⁵Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan;

Biallelic variants for autism....

20 ⁶Sana Medical Genetics Laboratory, Qazvin, Iran; Reference Laboratory of Qazvin Medical

21 University, Qazvin, Iran;

22 ⁷Science and Environment Sector, ICESCO, Rabat, Kingdom of Morocco;

23 ⁸Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health, Toronto, ON,

24 Canada;

25 ⁹Department of Psychiatry, State University of New York at Buffalo; Jacobs School of Medicine

26 and Biomedical Sciences, Buffalo, NY, USA;

27 ¹⁰Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia;

28 ¹¹Department of Educational Sciences, Farhangian University, Tehran, Iran;

29 ¹²Center for Psychiatric Research, Maine Medical Center Research Institute, 509 Forest Avenue,

30 Portland, ME, 04101, USA;

31 ¹³Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA, 02110, USA;

32 ¹⁴Department of Psychiatry, Maine Medical Center, 22 Bramhall Street, Portland, ME, 04102,

33 USA;

34 ¹⁵Autism Research & Treatment Center, Department of Physiology, Faculty of Medicine,

35 National Plan for Science and Technology (NPST), King Saud University, Riyadh, Saudi Arabia;

36 ¹⁶Department of Psychiatry, Harvard Medical School, Boston, MA, USA;

37 ¹⁷The University of Child Health Sciences, Children's Hospital, Lahore, Pakistan;

38 ¹⁸Human Genetics Institute of New Jersey and Department of Genetics, Rutgers University,

39 Piscataway, NJ, USA;

¹⁹Department of Psychiatry, Queens University Kingston, Kingston, ON, Canada;

Biallelic variants for autism....

²⁰Division of Psychiatry, University College London, London, UK;

40 ²¹Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

41 §Equal contribution

42 *Correspondence should be addressed to:

43 Dr. John B. Vincent, Brain Molecular Science, Campbell Family Mental Health Research Institute,

44 Centre for Addiction and Mental Health (CAMH), 250 College Street, Toronto, ON, Canada, M5T

45 1R8; Email: john.vincent@camh.ca

46 Dr. Muhammad Ayub, Division of Psychiatry, University College London, 149 Tottenham Ct Rd,

47 London W1T 7NF, United Kingdom. Email: m.ayub@ucl.ac.uk

48

Biallelic variants for autism....

49 **Abstract**

50 **Background:** Autism spectrum disorder (ASD) is a neurodevelopmental disorder that affects
51 about 1 in 36 children in the united states, imposing enormous economic and socioemotional
52 burden on families and communities. Genetic studies of ASD have identified *de novo* copy
53 number variants (CNVs) and point mutations that contribute significantly to the genetic
54 architecture, but the majority of these studies were conducted in populations unsuited for
55 detecting autosomal recessive (AR) inheritance. However, several ASD studies in
56 consanguineous populations point towards AR as an under-appreciated source of ASD variants.

57 **Methods:** We used whole exome sequencing to look for rare variants for ASD in 115 proband-
58 mother-father trios from populations with high rates of consanguinity, namely Pakistan, Iran,
59 and Saudi Arabia. Consanguinity was assessed through microarray genotyping.

60 **Results:** We report 84 candidate disease-predisposing single nucleotide variants and indels,
61 with 58% biallelic, 25% autosomal dominant/*de novo*, and the rest X-linked, in 39 trios. 52% of
62 the variants were loss of function (LoF) or putative LoF (pLoF), and 47% nonsynonymous. We
63 found an enrichment of biallelic variants, both in sixteen genes previously reported for AR ASD
64 and/or intellectual disability (ID) and 32 previously unreported AR candidate genes (including
65 *DAGLA*, *ENPP6*, *FAXDC2*, *ILDR2*, *KSR2*, *PKD1L1*, *SCN10A*, *SHH*, and *SLC36A1*). We also identified
66 eight candidate biallelic exonic loss CNVs.

67 **Conclusions:** The significant enrichment for biallelic variants among individuals with high F_{roh}
68 coefficients, compared with low F_{roh} , either in known or candidate AR genes, confirms that

Biallelic variants for autism....

69 genetic architecture for ASD among consanguineous populations is different to non-
70 consanguineous populations. Assessment of consanguinity may assist in the genetic diagnostic
71 process for ASD.

72 **Keywords:** Autism spectrum disorder; Trio; Autosomal recessive; Consanguinity; Biallelic;

73 Candidate Genes

74

75

Biallelic variants for autism....

76 **Introduction**

77 Autism spectrum disorder (ASD) is characterized by deficits in social communication,
78 repetitive/restricted behaviours and interests. Apart from a small percentage of individuals who
79 recover (1), ASD is a life-long condition and only about 20% have good outcomes, as reported in
80 a recent meta-analysis of longitudinal studies (2). Phenotypically, individuals with ASD are
81 heterogeneous in their level of intellectual functioning, and co-morbid psychiatric and
82 behavioural problems. These factors play an important role in the long term end points of the
83 disease (3). In a systematic review the prevalence of ASD was estimated to be 0.76%
84 internationally (4). In another systematic review of international data, the median estimate was
85 62/10,000 (5). In this review, the ASD prevalence showed little variation by geographic region,
86 ethnic, cultural and socioeconomic factors (5).

87 The reported prevalence of ASD has increased with time. In the 1960s it was estimated
88 to affect as few as 1 in 10,000 individuals (5), prevalence studies from the 1980s suggested that
89 as many as 72 in 10,000 individuals had ASD, rising to 1% in the 2000s (5,6). More recent
90 studies report prevalence rates of more than 2%. (7–9). In the United States the prevalence
91 across eleven sites in 2016 was 18.5 per 1,000 (one in 54) children (10), and increasing to one
92 in 36 in the most recent report (11). This increase is partly due to changes in diagnostic criteria,
93 reporting practices, and increased awareness (12–15).

94 A systematic review of literature from South Asian countries reported a prevalence of ASD
95 in the range of 0.09-1.07 % (16). To date, there has been no community study of ASD prevalence
96 in Pakistan. Studies from child psychiatry clinics reported rates of 2.4% and 3.2%, 4.5%, 5% (17–

Biallelic variants for autism....

97 20). Clinical services and special schools for ASD are available in Pakistan, but are typically limited
98 to major cities (21). The literature on clinical presentation is limited. One study with a small
99 sample size shows symptoms consistent with studies elsewhere in the world (22).

100 Consanguineous marriages lead to a marked increase in the frequency of rare recessive
101 disorders (23,24). Many genetic variants will only be pathogenic in recessive form; this includes
102 variants for ID, and almost certainly for ASD too. Populations with a high proportion of
103 consanguinity have been important for describing autosomal recessive genes in ID in Pakistan
104 (25,26), Iran (27,28), Syria (29), and Saudi Arabia (30), yet, to date, relatively few reports of AR
105 genes underlying ASD in consanguineous populations have been published (31–33). Previous
106 work has highlighted recessive inheritance as an important component of the genetic
107 architecture of ASD. For instance, a large study of consanguineous versus non-consanguineous
108 families in India concluded that consanguinity increases the risk for ASD with an odds ratio of
109 3.22 (34). Morrow and colleagues used SNP microarrays to map homozygous loci in 104 small
110 ASD families from the Middle East, Turkey and Pakistan, finding homozygous deletions
111 implicating *SLC9A9*, *PCDH10*, *CNTN3* and others (31).

112 Research in outbred populations also supports AR inheritance as an important piece of
113 the genetic puzzle for ASD. For example, it has been estimated that loss-of-function (LoF)
114 recessive mutations contribute 3% of ASD genetics in two US-based case-control cohorts (35).
115 These findings are not limited to population isolates or ethnic subgroups (36,37). Identification
116 of recessive genes in outbred populations is problematic, as the analysis pipelines for WES/WGS
117 data are non-optimal for discovering compound heterozygous mutations.

Biallelic variants for autism....

118 Despite the higher prevalence of recessive inheritance in consanguineous populations,
119 data from studies of developmental disorder (DD) suggest that *de novo* variants are also
120 prominent, albeit in a lower proportion e.g. in a UK study of 6040 families from the Deciphering
121 Developmental Disorders (DDD) study, individuals of Pakistani ancestry had 29.8% *de novo*
122 compared with 49.9% in the European ancestry UK population (38). In an Iranian ID study, the
123 *de novo* rate was 27.86% (39).

124 Describing the genetic architecture of ASD is an important step towards
125 understanding the pathogenesis of the disorder. There has been significant progress to date,
126 and studies of ASD have shown that *de novo* copy number variants (CNVs) and point mutations
127 play a prominent role, however, the majority of these studies have been conducted in outbred
128 populations (40). Here, we report on a study of 84 genetic and 11 genomic variants (eight
129 homozygous; 3 heterozygous) from a cohort of 115 ASD trios from three countries with a high
130 frequency of consanguineous marriages (Pakistan, Iran, and Saudi Arabia).

131 **Materials and Methods**

132 **Trio Family Ascertainment**

133 Institutional Research Ethics Board approval was received from the Centre for Addiction and
134 Mental Health (CAMH) and the recruitment sites. A summary of the cohorts, collaborator
135 contributions, ascertainment, and assessment tools, is in Table 1. Overall, we have collected
136 DNA from 115 trios: 62 trios from Pakistan, 40 trios from Iran, and 13 trios from Saudi Arabia,
137 comprised of 345 individuals.

Biallelic variants for autism....

138 **Whole Exome Sequencing, Alignment and Variant Calling**

139 Whole Exome Sequencing (WES) was performed on all samples using the ThruPLEX DNA-Seq
140 (Rubicon Genomics) Library Preparation Kit with the Agilent SureSelect V5 Exome Capture kit.
141 DNA was sheared using a Covaris ME220 Focused-Sonicator 200 bp, which was verified using a
142 Agilent 2100 Bioanalyzer System for fragment length distribution and quantification. All trios
143 were sequenced on Illumina HiSeq 2500 or NovaSeq sequencing systems. Details of read QC,
144 alignment, variant calling and prioritization are provided in Supplementary Materials, and
145 summarized in Figure 1. Fifteen trios were previously run using the Ion Proton platform/Ion
146 Ampliseq™ Exome kit (Life Technologies)- all were re-run using the Illumina platform except trio
147 IABB3, for which a causative frameshifting deletion was detected in the VPS13B/Cohen
148 syndrome gene.

149 **Microarray genotyping and analysis.**

150 Microarrays were run using DNA from 104 of the 115 ASD probands (where sufficient DNA was
151 available), including 13 using Affymetrix CytoScanHD, 87 using Illumina CoreExome, and four
152 with both arrays. CoreExome data in PLINK format was used for runs-of-homozygosity (RoH)
153 analysis, using PLINK 1.9 (<http://pngu.mgh.harvard.edu/purcell/plink>). RoH data was used to
154 generate an F-coefficient of consanguinity for the probands (and affected siblings), F_{RoH} , as
155 described in McQuillan et al, 2008 (41), where $F_{\text{roh}} = \sum L_{\text{roh}}/L_{\text{auto}}$. Autosome size L_{auto} was
156 estimated at 2,673,768 Kb. The CytoScanHD data was analysed using Chromosome Analysis
157 Suite (ChAS), and a loss of heterozygosity (LoH) score was generated. For four samples that
158 were run on both Illumina CoreExome and Affymetrix CytoScanHD arrays (probands from trios

Biallelic variants for autism....

159 IABB2, IABB3, IABB4, and IABB5), we were able to generate both F_{roh} and LoH scores, which, as
160 the relationship was almost linear (Pearson $R^2 = 0.9971$) allowed us to convert LoH scores from
161 CytoScanHD microarrays to F_{roh} (Supplementary Materials). Comparison statistics were
162 performed using GraphPad (<https://www.graphpad.com/>).

163 **Copy Number Variant (CNV) analysis**

164 CNV analysis of the CytoScanHD array data was performed using ChAS and PennCNV; for
165 CoreExome data by the Illumina Genome Suite/CNVpartition and PennCNV. Evidence of
166 homozygous loss CNVs was cross-references with WES data, using the Integrated Genome
167 Viewer v2.3.5 (IGV: <https://software.broadinstitute.org/software/igv/>; (42), and CNVs
168 corroborated in this manner were then checked by PCR. Further
169 analysis/prioritization/validation of CNVs, including using WES data, is given in Supplementary
170 Materials.

171 **Cross-referencing with other datasets**

172 In order to evaluate the strength of candidacy of the variants/genes identified here or to find
173 supporting evidence, we cross-referenced our findings with other datasets listed below. We
174 identified rare variants in the candidate genes we report here (Tables 2-4) that were either: 1.
175 *De novo*, 2. Heterozygous LoF but status either *de novo* or unknown; 3. Biallelic (i.e.
176 homozygous); 4. Putative biallelic (possibly compound heterozygous, but phasing unknown); 5.
177 X-linked in males, maternally inherited. Data are shown in Supplementary File 1.

Biallelic variants for autism....

178 **MSSNG:** More than 13,000 individuals from the Autism Genetic Research Exchange (AGRE)
179 repository and other cohorts have been whole-genome sequenced, through Autism Speaks, and
180 data made available through the MSSNG database (<https://research.mss.ng>; db7 (43)). MSSNG
181 data was accessed in May 2024.

182 **SFARI: SSC biallelic:** The Simons Simplex Collection (SSC) includes 2,600 simplex autism or
183 related developmental disorder families. WES data is available for ~2,500 of these families,
184 biallelic variants for our gene list were searched using the GPF browser
185 (<https://gpf.sfari.org/gpf19/datasets/SSC/browser>). Putative compound heterozygous variants
186 criteria for minor allele frequency (MAF) in SSC exome, gnomAD exome and genome
187 frequencies, of <0.001, or, for missense variants, MCP scores >1 and CADD scores >18. **SVIP**
188 **biallelic:** the autism Simons Variation in Individuals Project (SVIP) dataset was searched for
189 putative biallelic variants through the browser gpf.sfari.org/gpf19/datasets/SVIP/browser.
190 Putative compound heterozygous variants checked for criteria including minor allele frequency
191 (MAF) in SSC exome, gnomAD exome and genome frequencies, of <0.001, or, for missense
192 variants, MCP scores >1 and CADD scores >18.

193 **Deciphering Developmental Disorders (DDD) study:** includes sequence data for ~14,000
194 children; this dataset was searched for variants in genes overlapping with our study through the
195 known developmental genes list (<https://decipher.sanger.ac.uk/ddd#ddgenes>), as well as the
196 list of research variants (<https://decipher.sanger.ac.uk/ddd#research-variants>), which are 2,723
197 variants of unknown significance from 4,293 children. For *de novo* variants, all are constitutive,
198 unless specifically noted as mosaic here. CNV variants are not included here.

Biallelic variants for autism....

199 **Autism Sequencing Consortium (ASC):** genes with *de novo* variants, either in the control set or
200 case set, from ASC exome analysis browser (<https://asc.broadinstitute.org/>). This dataset lists
201 numbers of *de novo* protein-truncating variants, as well as *de novo* missense variants with MCP
202 scores either 1-2 or ≥ 2 . The ASC dataset includes 6,430 probands, and includes the SSC data.

203 **DeRubeis:** genes with *de novo* variants reported in the DeRubeis et al, 2014 study, with either
204 LoF or missense variants (44). As subject IDs were not reported, overlap with other studies
205 recorded here is not possible.

206 **AutismKB:** additional studies where variants have been reported for the genes are taken from
207 the Autism Knowledge Base (http://db.cbi.pku.edu.cn/autismkb_v2/quick_search.php), (45).

208 **Neuroanatomical Enrichment Analysis**

209 The Allen Adult Human Brain Atlas (46), Brainspan (47), and a single-cell atlas of the mouse
210 nervous system (48) were used to test for neuroanatomically specific expression. For each
211 gene, expression was standardized across regions or cell types. For these compartments, each
212 gene was then ranked from most specific to most depleted. The area under the receiver
213 operating statistic (AUC) was used to quantify specific expression for the genes of interest
214 within a region or cell cluster. The Mann-Whitney U test was used to test statistical significance,
215 and the Benjamini–Hochberg procedure (49) was used to correct for multiple tests. In addition,
216 in order to explore whether our candidate genes may contribute to electrophysiological and
217 morphological phenotypes in neurons we cross-referenced gene expression correlates with
218 electrophysiological phenotypes through a dataset published by Bomkamp et al, 2019 (50).

219

Biallelic variants for autism....

220 **Results**

221 We ascertained, phenotyped, collect blood and/or saliva for DNA extraction, and performed
222 whole exome sequencing (mean depth: 27.29; average % coverage at 30X=31.01; average %
223 coverage at 100X=7.32; see Supplementary File 1) from 115 ASD proband
224 (91M:24F)/mother/father trios (62 from Pakistan, 40 from Iran, and 13 from Saudi Arabia), for a
225 total of 345 subjects (Table1). In addition, microarrays were run on 104 of the ASD probands,
226 providing data for CNV and ROH analyses.

227 **Whole Exome Sequencing:** We discovered 84 SNVs or indels through our analysis pipeline,
228 including 49 homozygous autosomal variants, 20 autosomal *de novo* (and 1 inherited) variants,
229 and 5 *de novo* and 9 maternally inherited X-linked variants.

230 **Biallelic mutations (Table 2):** We identified homozygous variants (7 LoF or pLoF; 9
231 nonsynonymous; 1 in-frame del) in 17 genes that have been previously reported to be
232 associated with autosomal recessive non-syndromic ID, including *BTN3A2* (30), *CC2D1A* (MIM
233 608443; MRT3; (51)), *LINS1* (28), *MADD* (30), *MTHFR* (29), *RSRC1* (52,53), *TECPR2* (30) and
234 *ZNF335* (27), or for syndromic or metabolic forms of autosomal recessive ID, including *AGA*
235 (aspartylglucosaminuria), *ASL* (arginosuccinic aciduria), *ASPA* (aspartoacylase
236 deficiency/Canavan disease), and *HTRA2* (3-methylglutaconic aciduria). Three genes, *CC2D1A*,
237 *DEAF1*, and *VPS13B* have also previously been associated with ASD or autistic features (94–96;
238 (57)). Biallelic mutations in *DEAF1* are known to cause neurodevelopmental disorder with
239 hypotonia, impaired expressive language, with or without seizures (MIM 617171). LoF variants
240 were reported for new candidate genes *ENPEP*, *DAGLA*, *FAXDC2*, *GIMAP8*, *HRNR*, *ILDR2*,

Biallelic variants for autism....

241 *SLC36A1*, *SCN10A*, *VPS16*, *ZNF766*, and pLoF (such as canonical splice site variants) in *CNPY4*,
242 *DENND1B*, *LRRC34*, *PKD1L1*, and *PPP1R36*. *VPS16* has previously been reported for autosomal
243 dominant dystonia (MIM 608559), and *PKD1L1* for AR visceral heterotaxy 8 (MIM 617205).
244 Heterozygous missense and LoF mutations in *SHH* are known to be involved in autosomal
245 dominant holoprosencephaly 3 (HPE3; MIM 142945), and so it is somewhat surprising to find a
246 homozygous missense variant associated with a milder phenotype and with no obvious HPE3-
247 related dysmorphic features. The Asn69Ile variant in *SHH* substitutes an asparagine for
248 isoleucine at a residue that is conserved across vertebrates, is predicted to be damaging, and is
249 found in heterozygous form in only 21 out of 1.6E6 gnomAD (v4.1.0) alleles, and no
250 homozygotes.

251 In one trio (trio SMPA21) we report a homozygous stop-gain variant in *DAGLA*, for which
252 rare heterozygous variants were reported to be associated with neurodevelopmental disorders,
253 including autism (58). SFARI also lists this as a strong candidate for a ASD disease gene (gene
254 score of 2; <https://gene.sfari.org/>). We also report homozygous missense variants in novel
255 candidate genes *ANO10*, *CABP2*, *CAPSL*, *CLCA4*, *CPM*, *DNAH8*, *ERMP1*, *KSR2*, *RANBP9*, *RASAL2*,
256 *TMEM25*, *TRIM3*, *VPS16*, and *WDR90*, plus in *SGSM3* and *EPHB1*, for which *de novo* variants in
257 have been reported for ASD (59), and are listed respectively as strong candidate and suggestive
258 evidence in SFARI (scores of 2 and 3, respectively).

259 Although not focused on consanguineous populations, WGS data from the MSSNG
260 study, as well as WES studies such as DDD and SFARI, support a number of our candidate AR
261 genes (see Supplementary File 1), with homozygous rare variants in *DNAH7* (MSSNG), *DNAH8*

Biallelic variants for autism....

262 (MSSNG), *CAPSL* (MSSNG), and *CYP2A7* (MSSNG), and putative compound heterozygous
263 damaging rare variants in *DNAH8* (in three MSSNG individuals), *SCN10A* (DDD), and *WDR90*
264 (DDD)(see Supplementary File 1). There was also evidence of disease-causing biallelic variants
265 in known AR neurodevelopmental genes *MTHFR* (three homozygous; DDD), *AGA* (one
266 homozygous stop gain; DDD), *DEAF1* (two homozygous stop gain; MSSNG and DDD), *ZNF335*
267 (one homozygous missense, DDD; one putative compound heterozygous, DDD), *ASL* (one
268 homozygous missense; MSSNG), *CC2D1A* (one homozygous missense, MSSNG; two
269 homozygous LoF DDD), and *VPS13B* (six homozygous, nine putative compound heterozygous).

270 ***De novo* mutations (Table 3 & 4):** *De novo* dominant mutations have been shown to be a major
271 causal factor in ASD etiology. We identified 25 *de novo* variants (20 autosomal and 5 X-linked).
272 Among these genes, variants in four of them have been identified in previous studies (*MECP2*,
273 *MYT1L*, *SCN2A*, *ZNF292*). 14 of the 25 variants were LoF, three were putative LoF (splice site),
274 and the remainder were nonsynonymous. The mutations include genes that have been
275 implicated in other recent studies of ASD and/or ID. For instance, we report a *de novo*
276 hemizygous nonsynonymous mutation in *CLTRN* (on chromosome X). Hemizygous mutations in
277 *CLTRN* have recently been reported in several males with neutral aminoaciduria accompanied
278 with autistic features, anxiety, depression, compulsions and motor tics (60)- a clinical picture
279 reminiscent of the autosomal recessive Hartnup disorder (MIM 234500). There were also
280 several other genes with *de novo* variants that have not been associated with ASD (or ID)
281 previously, and may represent novel putative genes for ASD, and for other trios there are

Biallelic variants for autism....

282 variants in genes linked with other nervous system disorders, such as *DRP2* in Charcot-Marie-
283 Tooth disease (61).

284 Our study identified a *de novo* LoF mutation in *ZNF292* (NM_015021:c.6159_6160del;
285 p.Glu2054Lysfs*14) in two trios (IAU-65 (Iranian) and Autism-10 (Pakistani)). These two trios
286 and 26 additional families (from multiple studies and cohorts) with mutations in *ZNF292* were
287 reported recently (62).

288 Cross-referencing with other datasets, there was also support for new candidate
289 dominant/*de novo* autosomal genes, including *ECM1*, *SLAMF7*, *NCL*, *FAM53C*, *ADGRF2*,
290 *TANGO2*, *DGKZ*, *ATP2B1* (5 individuals), *CBFA2T3*, *RETN*, and *PPIL2* (see Supplementary File 1).
291 There was support for X-linked recessive (in males, maternally inherited or *de novo*) candidate
292 gene *NRK* (three individuals), *MAGEB2* (three individuals), *MAGEC1* (11 individuals), *MSN* (five
293 individuals), and *ZNF185* (one individuals).

294

295 **X-linked (inherited; Table 4):** Two mutations were identified in well-established ASD or ID
296 genes, namely, *AIFM1* (Cowchock syndrome; MIM 310490), and *MID2* (XLID101: MIM 300928).

297 **Splice site variants**

298 In addition to the detection of variants at canonical splice donor and splice acceptor sites
299 (Tables 2-4), use of SpliceAI suggests that, for the biallelic nonsynonymous variant in the known
300 ASD/ID gene *ASL* (trio SA7), an alternative explanation could be the generation of an alternative
301 splice donor by the cytosine to thymine transition at this site. However, other splice algorithms

Biallelic variants for autism....

302 such as https://www.fruitfly.org/seq_tools/splice.html do not support this, and molecular
303 experimental procedures may be needed to corroborate or refute this prediction.

304 **Copy Number Variants (Table 5 & 6)**

305 Eight autosomal biallelic loss CNVs were identified among five trios using microarray data, that
306 were subsequently validated through inspection of the WES data using IGV, and through
307 molecular methods, using PCR and/or Sanger sequencing. Of these implicated genes,
308 mutations/knock-outs of both *DHRS4* and *KLK15* have a neurobehavioral phenotype in mouse
309 models (Supplementary File 1). *DNAH7* is highly expressed in brain, and both SHPK
310 (sedoheptulokinase) and *WDR73* have high expression in cerebellum. Of the biallelic CNVs
311 identified, *WDR73* has previously been associated with the autosomal recessive Galloway-
312 Mowat syndrome 1 (MIM 251300), which includes microcephaly, delayed psychomotor
313 development and cerebellar atrophy. Determining the ASD causative genetic variation in many
314 of the probands with CNVs is difficult. The proband with the *WRD73*, *CYP2A7*, and *KLK15* CNVs
315 (trio IABB14) also has a biallelic splice mutation in the Canavan disease gene *ASPA*. Additionally,
316 the proband with the *SHPK* CNV (trio IABB2) also has a biallelic LoF mutation in the known ID
317 gene *DEAF1*, and the proband with the *SIRPB1* CNV (trio IAU79) has a biallelic non-frameshift
318 deletion in the known ID/spastic paraplegia gene *B4GALNT1*, complicating identification of the
319 molecular causation (see Supplementary File 1). A biallelic CNV loss implicates the gene *SEMG1*
320 in trio SMPA4, however expression of this gene is restricted to the seminal vesicle (see
321 Supplementary File 1), and thus unlikely to be related to the ASD phenotype.

Biallelic variants for autism....

322 There are also three large, multi-genic *de novo* CNV losses among the trios, which may
323 also be pathogenic (Supplementary Table S1).

324 **Neuroanatomical Enrichment Analysis**

325 Testing for regional and cell-type specific expression did not indicate clear anatomical
326 targets with higher expression of the candidate genes. Enrichment in the cerebellum and
327 cerebral cortex was observed in the BrainSpan human developmental atlas, but this was not
328 supported by either the mouse or adult human atlases. We found no consistent
329 neuroanatomical expression pattern for the identified genes, suggesting heterogeneity of
330 neural circuits disrupted.

331 **High consanguinity coefficient correlates with identification of biallelic variants**

332 Using microarray data we calculated the consanguinity coefficient F_{RoH} using autosomal RoH for
333 104 of the 115 trios. This included 13 trios for which LoH scores were converted to F_{RoH} using
334 the equation $F_{\text{RoH}}=(\text{LoH} - 0.0111)/1.034$ (see Methods and Supplementary Materials).
335 Comparison of the degree of consanguinity (using F_{RoH}) between 33 trios with biallelic variants
336 versus 20 trios with *de novo* and X-linked variants indicated a strongly significant shift (unpaired
337 *t* test (two-tailed): $p < 0.0001$; $df=51$; mean F_{RoH} for biallelic variants= 0.09003, S.E.M.=0.00672,
338 $N=33$; mean F_{RoH} for autosomal *de novo* and X-linked = 0.02955, S.E.M. = 0.00737, $N=20$). This is
339 also true for variants identified in known ASD/ID genes ($p = 0.0045$; $df=22$; mean F_{RoH} for biallelic
340 0.08146, $N=13$, S.E.M.=0.01019; mean F_{RoH} for autosomal *de novo* and X-linked = 0.03282,
341 $N=11$, S.E.M.=0.01159).(Figure 2A). Comparison also showed clear differences in F_{RoH} levels
342 between different cohorts, and country of ascertainment (Figure 2B & C).

Biallelic variants for autism....

343

344 **Discussion**

345 Many recent studies involving NGS in ASD have involved large cohorts, focusing predominantly
346 on dominant/*de novo* inheritance. This focus is largely driven by the fact that autosomal
347 recessive variants in novel genes are more difficult to identify in the outbred population.
348 Identification of candidate AR ASD genes through the study of consanguineous families should
349 help streamline the identification of biallelic mutations through clinical genetic screening in
350 outbred populations. Using whole exome trio analysis in consanguineous families, we have
351 enriched for recessive variants to assess the role these variants play in ASD in populations
352 where endogamy is common. This study of 115 trios has identified WES variants for 32 trios in
353 genes previously associated with ASD or other neurodevelopmental disorders, resulting in a
354 diagnostic yield of 28% (18 autosomal recessive, seven autosomal *de novo* plus one maternally
355 inherited, and six X-linked variants in known genes). With a further three trios with large, multi-
356 genic, loss CNVs validated experimentally as *de novo* and putatively pathogenic (Table 6), this
357 yield increases to 30%. There were many other variants identified that met filtering criteria
358 which could potentially represent novel ASD genes or targets. We present 32 new candidate
359 autosomal recessive variants/genes, including a biallelic variant in *SHH*, a gene associated with
360 autosomal dominant holoprosencephaly. Within this cohort we identified variants in five genes
361 that are associated with known metabolic syndromes (4.3% of the diagnosis cohort): *AGA*, *ASL*,
362 *HTRA2*, *ASPA*, and *MTHFR*. These genes may represent better clinical management
363 opportunities for patients, and potentially better therapies.

Biallelic variants for autism....

364 A number of the known ID genes identified among the 115 ASD trios have also previously
365 been reported for ASD or ASD-like features, e.g. *CC2D1A* (55,62,63), *VPS13B* (33), *DEAF1* (54),
366 *ZNF335* (64), *ZNF292* (65,66), *MYT1L* (66,67), and *SCN2A* (59,68,69). Of the candidate genes
367 identified here, *MSSNG*, *SFARI*, and other datasets provide putative support for the biallelic
368 genes, with homozygous variants in *DNAH7*, *ANO10*, *DNAH8*, *CAPSL*, *CYP2A7*, and *SIRPB1*, and
369 putative compound heterozygous variants in *DNAH7*, *DNAH8*, *SCN10A*, and *WDR90*, and for *de*
370 *novo*/dominant genes *NCL*, *SLAMF7*, *ADGRF2*, *DGKZ*, *ATP2B1*, *CBFA2T3*, *RETN*, and *PPIL2*
371 (Supplementary File 1).

372 For three of the known ASD or ID genes reported here, namely *ZNF292*, *SCN2A*, and *MECP2*,
373 mutations have been identified in two unrelated trios from our cohort. Mutations in the known
374 ASD gene *SCN2A* (68) were identified in two trios- both *de novo*. In addition, mutations were
375 identified in three other voltage-gated sodium channel members, including a biallelic stop gain
376 mutation in *SCN10A*, in which heterozygous gain of function missense mutations have
377 previously been linked to familial episodic pain syndrome 2 (FEPS2; MIM 615551)(70), as well as
378 *de novo* missense mutations in *SCN5A* and *SCN8A*. The *SCN8A* variant is predicted as damaging by
379 all algorithms tested, and mutations in this gene have previously been linked to AD developmental and
380 epileptic encephalopathy 13 (DEE13; MIM 614558). The *SCN5A* variant was predicted as benign by
381 several of the algorithms and is less likely to be related to ASD in this trio. The Arg267* mutation
382 identified in *MECP2* in trio SMPA78 has been frequently reported in cases of Rett syndrome. However
383 more C-terminal truncating mutations such as the Thr412Asnfs*5 mutation in trio IAU54 typically have a
384 significantly milder phenotype(71).

Biallelic variants for autism....

385 For some of the autosomal recessive candidate genes, there is additional support from
386 animal models. For instance, *Rasal2* (MGI:2443881) and *Vps16* (MGI:2136772) knockout mice
387 have behavioral/neurological and nervous system phenotypes
388 (<http://www.informatics.jax.org/>; Supplementary File 1). Additional discussion of mouse
389 models relevant to the candidate genes is provided in Supplementary Materials.

390 There are several trios for which there are two or more candidate variants (Supplementary
391 File 1). For some of these, there may be a variant that clearly delivers a more plausible
392 etiopathological explanation. For instance, for trio SMPA3 the biallelic change in *MTHFR*; for
393 trio IAH2, the biallelic LoF change in *TECPR2* (SPG49; MIM 615031; ID (30); hereditary sensory
394 neuropathy with ID (72)); for trio IABB2, the biallelic LoF variant in (*NEDHELS*; MIM 617171); for
395 trio IABB14, the biallelic splice mutation in *ASPA* (Canavan disease; MIM 271900).

396 Since our initial methodology used relatively stringent MAF cut-off criteria for biallelic
397 variants (<0.001), we attempted to justify this level by reiterating the analysis but with lower
398 thresholds (<0.01). Using the more relaxed criteria resulted in just two additional candidate
399 variants, in the genes *CLCA4* (gnomAD South Asian MAF=1.72E-3), and *RASAL2* (gnomAD South
400 Asian MAF=6E-3), but none in known neurodevelopmental genes. Our methodology was
401 particularly stringent regarding *de novo* nonsynonymous variants, owing to the large number of
402 likely spurious calls, and the inclusion of only variants predicted as damaging by all algorithms
403 used may have excluded some *bona fide* mutations. Other variants, particularly intronic or
404 intergenic, would also likely be missed by our approach. Also, a proportion of exons, and
405 particularly in GC-rich regions, are either missed or have low coverage in WES. Follow-up with

Biallelic variants for autism....

406 whole genome sequencing could be considered as a possible next step. However, parsing and
407 assessing rare non-coding variants is particularly challenging.

408 It was recently estimated in the DDD cohort that recessive variants make up 3.6% of
409 diagnoses, whereas *de novo* variants contribute 48.6% of variants (38). The same study also
410 compared homozygous variants in a narrowly defined group of Pakistani Ancestry in the British
411 Isles (PABI), which is most like our cohort (38). The PABI cohort had 356 (333 undiagnosed)
412 probands, 110 of whom (30.9%) had biallelic coding candidate variants, approximately half of
413 which are in known DD genes and half in novel candidates (38). For comparison, our study
414 reports very similar yields for recessive variants, with 15% of probands with biallelic variants in
415 known ASD/ID genes (17/115), or 30% including those with biallelic variants in novel candidate
416 genes (35/115). We report 28 *de novo* variants (20 autosomal, five X-linked, three CNVs) in 17
417 of 115 individuals (15%), which is somewhat lower than those reported for the PABI cohort
418 (29.8%). This difference is most likely due to differences in the methodologies or stringency
419 used for calling *de novo* variants in the respective studies.

420 Comparison of consanguinity (F_{RoH}) between trios with biallelic variants (either known or
421 candidates) versus trios with *de novo* and X-linked variants indicated a strongly significant shift..
422 Thus, unsurprisingly, the chances of finding biallelic rare variants is strongly associated with
423 higher consanguinity, and should be a consideration for diagnostic genetic analysis.

424 Overall, the findings demonstrate the importance of autosomal recessive mutations in
425 ASD in countries, or in cohorts, with high rates of consanguinity. In countries where
426 consanguinity is rare, when screening ASD individuals' genomes attention should still be paid to

Biallelic variants for autism....

427 the relatedness of the parents, and, for those with a high F-coefficient, attention should be
428 focused on biallelic variants. Additionally, the candidate genes reported here should be
429 examined for both autozygous *and* allozygous mutations in outbred populations, just as would
430 be done for more established autosomal recessive gene disorders.

431

432 **Declaration of Interests Statement**

433 L.F. owns shares in Quince Therapeutics and has received consulting fees from PeopleBio Co., GC
434 Therapeutics Inc., Cortexyme Inc., and Keystone Bio. M.A. is co-founder and director of Institute of
435 Omics and Health Research, Lahore, a research organization. The organization was not involved
436 in the research on which this manuscript is based. All other authors declare no competing
437 interests.

438

439

440 **Acknowledgements**

441 The authors thank the families for their participation in this study. We acknowledge the
442 assistance of Natalie Freeman with PLINK microarray analysis, and of Stephen Pastore with the
443 preparation of violin plots using R software. This work was supported by grants from the
444 Canadian Institutes of Health Research to JBV (#MOP-102758 and #PJT-156402), also a Brain &
445 Behavior Research Foundation (BBRF/NARSAD) Young Investigator Award to NV. RH was
446 supported by a Peterborough K.M. Hunter Charitable Foundation Graduate Scholarship. AR and
447 AH were supported by International Research Fellowship Program scholarships from the

Biallelic variants for autism....

448 Pakistani Higher Education Commission. CS was supported by a Summer University Research
449 Program award from the Institute of Medical Science, University of Toronto. Computations
450 were performed on the CAMH Specialized Computing Cluster. The SCC is funded by The Canada
451 Foundation for Innovation, Research Hospital Fund. Additional acknowledgements are included
452 in Supplementary Materials

453 **Data and code availability**

454 New variants reported here are available through ClinVar SUB14665852, and SCV accession
455 numbers are included in Supplementary File 1. Microarray genotype data and whole exome sequence
456 data will be made available from the corresponding author upon request.

457

458 **References**

- 459 1. Helt M, Kelley E, Kinsbourne M, Pandey J, Boorstein H, Herbert M, et al. Can children with
460 autism recover? If so, how? *Neuropsychol Rev.* 2008 Dec;18(4):339–66.
- 461 2. Mason D, Capp SJ, Stewart GR, Kempton MJ, Glaser K, Howlin P, et al. A Meta-analysis of
462 Outcome Studies of Autistic Adults: Quantifying Effect Size, Quality, and Meta-regression. *J*
463 *Autism Dev Disord.* 2021 Sep;51(9):3165–79.
- 464 3. Lai MC, Kassee C, Besney R, Bonato S, Hull L, Mandy W, et al. Prevalence of co-occurring
465 mental health diagnoses in the autism population: a systematic review and meta-analysis.
466 *Lancet Psychiatry.* 2019 Oct;6(10):819–29.
- 467 4. Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG. The epidemiology and
468 global burden of autism spectrum disorders. *Psychol Med.* 2015 Feb;45(3):601–13.
- 469 5. Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcín C, et al. Global Prevalence of
470 Autism and Other Pervasive Developmental Disorders. *Autism Res.* 2012 Jun;5(3):160–79.
- 471 6. Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, et al. Prevalence of
472 disorders of the autism spectrum in a population cohort of children in South Thames: the
473 Special Needs and Autism Project (SNAP). *Lancet Lond Engl.* 2006 Jul 15;368(9531):210–
474 5.

Biallelic variants for autism....

- 475 7. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal
476 Investigators, Centers for Disease Control and Prevention (CDC). Prevalence of autism
477 spectrum disorder among children aged 8 years - autism and developmental disabilities
478 monitoring network, 11 sites, United States, 2010. *Morb Mortal Wkly Rep Surveill Summ*
479 Wash DC 2002. 2014 Mar 28;63(2):1–21.
- 480 8. Kim YS, Leventhal BL, Koh YJ, Fombonne E, Laska E, Lim EC, et al. Prevalence of autism
481 spectrum disorders in a total population sample. *Am J Psychiatry*. 2011 Sep;168(9):904–12.
- 482 9. Lundström S, Reichenberg A, Anckarsäter H, Lichtenstein P, Gillberg C. Autism phenotype
483 versus registered diagnosis in Swedish children: prevalence trends over 10 years in general
484 population samples. *BMJ*. 2015 Apr 28;350:h1961.
- 485 10. Maenner MJ. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years —
486 Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016.
487 *MMWR Surveill Summ* [Internet]. 2020 [cited 2021 Jun 5];69. Available from:
488 <https://www.cdc.gov/mmwr/volumes/69/ss/ss6904a1.htm>
- 489 11. Maenner MJ. Prevalence and Characteristics of Autism Spectrum Disorder Among Children
490 Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites,
491 United States, 2020. *MMWR Surveill Summ* [Internet]. 2023 [cited 2024 Sep 16];72.
492 Available from: <https://www.cdc.gov/mmwr/volumes/72/ss/ss7202a1.htm>
- 493 12. Fombonne E. Editorial: The rising prevalence of autism. *J Child Psychol Psychiatry*.
494 2018;59(7):717–20.
- 495 13. Hansen SN, Schendel DE, Parner ET. Explaining the increase in the prevalence of autism
496 spectrum disorders: the proportion attributable to changes in reporting practices. *JAMA*
497 *Pediatr*. 2015 Jan;169(1):56–62.
- 498 14. Lord C, Brugha T, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism spectrum
499 disorder. *Nat Rev Dis Primer*. 2020 Jan 16;6(1):5.
- 500 15. Rødgaard EM, Jensen K, Vergnes JN, Soulières I, Mottron L. Temporal Changes in Effect
501 Sizes of Studies Comparing Individuals With and Without Autism: A Meta-analysis. *JAMA*
502 *Psychiatry*. 2019 Nov 1;76(11):1124–32.
- 503 16. Hossain MD, Ahmed HU, Jalal Uddin MM, Chowdhury WA, Iqbal MS, Kabir RI, et al.
504 Autism Spectrum disorders (ASD) in South Asia: a systematic review. *BMC Psychiatry*.
505 2017 Aug 1;17(1):281.
- 506 17. Imran N, Bhatti MR, Anwar A, Najmi F, Haider II. Children’s Mental Health: Pattern of
507 referral, distribution of disorders and service use in child psychiatry outpatient setting. *Pak J*
508 *Med Sci*. 2012;28(1):22–6.
- 509 18. Syed EU, Hussein SA, Yousafzai AW. Developing Services with Limited Resources:
510 Establishing a CAMHS in Pakistan. *Child Adolesc Ment Health*. 2007;12(3):121–4.

Biallelic variants for autism....

- 511 19. Tareen A, Mirza I, Minhas A, Minhas F, Rahman A. Developing a child and adolescent
512 mental health service in a low-income country: a global partnership model. *Psychiatr Bull.*
513 2009 May;33(5):181–3.
- 514 26. Sarwat A, Ali SMI, Ejaz MS. Mental health comorbidity in children: a hospital based study
515 in child psychiatry clinic. *Pak J Med Sci.* 2009;25(6):982–5.
- 516 21. Minhas A, Vajaratkar V, Divan G, Hamdani SU, Leadbitter K, Taylor C, et al. Parents’
517 perspectives on care of children with autistic spectrum disorder in South Asia – Views from
518 Pakistan and India. *Int Rev Psychiatry.* 2015 May 4;27(3):247–56.
- 519 22. Rauf NK, Anis-ul-Haq null, Aslam N, Anjum U. Characteristic symptoms and adaptive
520 behaviors of children with autism. *J Coll Physicians Surg--Pak JCPSP.* 2014 Sep;24(9):658–
521 62.
- 522 23. Bunday S, Alam H. A five-year prospective study of the health of children in different ethnic
523 groups, with particular reference to the effect of inbreeding. *Eur J Hum Genet EJHG.*
524 1993;1(3):206–19.
- 525 24. Modell B, Darr A. Science and society: genetic counselling and customary consanguineous
526 marriage. *Nat Rev Genet.* 2002 Mar;3(3):225–9.
- 527 25. Harripaul R, Vasli N, Mikhailov A, Rafiq MA, Mittal K, Windpassinger C, et al. Mapping
528 autosomal recessive intellectual disability: combined microarray and exome sequencing
529 identifies 26 novel candidate genes in 192 consanguineous families. *Mol Psychiatry.*
530 2018;23(4):973–84.
- 531 26. Riazuddin S, Hussain M, Razzaq A, Iqbal Z, Shahzad M, Polla DL, et al. Exome sequencing
532 of Pakistani consanguineous families identifies 30 novel candidate genes for recessive
533 intellectual disability. *Mol Psychiatry.* 2017 Nov;22(11):1604–14.
- 534 27. Hu H, Kahrizi K, Musante L, Fattahi Z, Herwig R, Hosseini M, et al. Genetics of intellectual
535 disability in consanguineous families. *Mol Psychiatry.* 2018 Jan 4;
- 536 28. Najmabadi H, Hu H, Garshasbi M, Zemojtel T, Abedini SS, Chen W, et al. Deep sequencing
537 reveals 50 novel genes for recessive cognitive disorders. *Nature.* 2011 Sep 21;478(7367):57–
538 63.
- 539 29. Reuter MS, Tawamie H, Buchert R, Hosny Gebril O, Froukh T, Thiel C, et al. Diagnostic
540 Yield and Novel Candidate Genes by Exome Sequencing in 152 Consanguineous Families
541 With Neurodevelopmental Disorders. *JAMA Psychiatry.* 2017 Mar 1;74(3):293–9.
- 542 30. Anazi S, Maddirevula S, Salpietro V, Asi YT, Alsahli S, Alhashem A, et al. Expanding the
543 genetic heterogeneity of intellectual disability. *Hum Genet.* 2017 Nov;136(11–12):1419–29.
- 544 31. Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, Hill RS, et al. Identifying autism loci
545 and genes by tracing recent shared ancestry. *Science.* 2008 Jul 11;321(5886):218–23.

Biallelic variants for autism....

- 546 32. Al-Mubarak B, Abouelhoda M, Omar A, AlDhalaan H, Aldosari M, Nester M, et al. Whole
547 exome sequencing reveals inherited and de novo variants in autism spectrum disorder: a trio
548 study from Saudi families. *Sci Rep*. 2017 Jul 18;7(1):5679.
- 549 33. Yu TW, Chahrour MH, Coulter ME, Jiralerspong S, Okamura-Ikeda K, Ataman B, et al.
550 Using whole-exome sequencing to identify inherited causes of autism. *Neuron*. 2013 Jan
551 23;77(2):259–73.
- 552 34. Mamidala MP, Kalikiri MK, Praveen Kumar PTV, Rajesh N, Vallamkonda OR, Rajesh V.
553 Consanguinity in India and its association with autism spectrum disorder. *Autism Res Off J*
554 *Int Soc Autism Res*. 2015 Apr;8(2):224–8.
- 555 35. Lim ET, Raychaudhuri S, Sanders SJ, Stevens C, Sabo A, MacArthur DG, et al. Rare
556 complete knockouts in humans: population distribution and significant role in autism
557 spectrum disorders. *Neuron*. 2013 Jan 23;77(2):235–42.
- 558 36. Howrigan DP, Simonson MA, Davies G, Harris SE, Tenesa A, Starr JM, et al. Genome-wide
559 autozygosity is associated with lower general cognitive ability. *Mol Psychiatry*.
560 2016;21(6):837–43.
- 561 37. Kaiser VB, Svinti V, Prendergast JG, Chau YY, Campbell A, Patarcic I, et al. Homozygous
562 loss-of-function variants in European cosmopolitan and isolate populations. *Hum Mol Genet*.
563 2015 Oct 1;24(19):5464–74.
- 564 38. Martin HC, Jones WD, McIntyre R, Sanchez-Andrade G, Sanderson M, Stephenson JD, et
565 al. Quantifying the contribution of recessive coding variation to developmental disorders.
566 *Science*. 2018 07;362(6419):1161–4.
- 567 39. Kahrizi K, Hu H, Hosseini M, Kalscheuer VM, Fattahi Z, Beheshtian M, et al. Effect of
568 inbreeding on intellectual disability revisited by trio sequencing. *Clin Genet*.
569 2019;95(1):151–9.
- 570 40. Ramaswami G, Geschwind DH. Genetics of autism spectrum disorder. *Handb Clin Neurol*.
571 2018;147:321–9.
- 572 41. McQuillan R, Leutenegger AL, Abdel-Rahman R, Franklin CS, Pericic M, Barac-Lauc L, et
573 al. Runs of homozygosity in European populations. *Am J Hum Genet*. 2008 Sep;83(3):359–
574 72.
- 575 42. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al.
576 Integrative genomics viewer. *Nat Biotechnol*. 2011 Jan;29(1):24–6.
- 577 43. Yuen RKC, Merico D, Cao H, Pellecchia G, Alipanahi B, Thiruvahindrapuram B, et al.
578 Genome-wide characteristics of de novo mutations in autism. *NPJ Genomic Med*. 2016 Aug
579 3;1:160271–1602710.
- 580 44. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Synaptic,
581 transcriptional and chromatin genes disrupted in autism. *Nature*. 2014 Nov
582 13;515(7526):209–15.

Biallelic variants for autism....

- 583 45. Yang C, Li J, Wu Q, Yang X, Huang AY, Zhang J, et al. AutismKB 2.0: a knowledgebase
584 for the genetic evidence of autism spectrum disorder. Database J Biol Databases Curation.
585 2018 Jan 1;2018.
- 586 46. Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, et al. An
587 anatomically comprehensive atlas of the adult human brain transcriptome. Nature. 2012 Sep
588 20;489(7416):391–9.
- 589 47. Li M, Santpere G, Imamura Kawasawa Y, Evgrafov OV, Gulden FO, Pochareddy S, et al.
590 Integrative functional genomic analysis of human brain development and neuropsychiatric
591 risks. Science. 2018 14;362(6420).
- 592 48. Zeisel A, Hochgerner H, Lönnerberg P, Johnsson A, Memic F, van der Zwan J, et al.
593 Molecular Architecture of the Mouse Nervous System. Cell. 2018 Aug 9;174(4):999-
594 1014.e22.
- 595 49. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
596 Approach to Multiple Testing. J R Stat Soc Ser B Methodol. 1995 Jan;57(1):289–300.
- 597 50. Bomkamp C, Tripathy SJ, Bengtsson Gonzales C, Hjerling-Leffler J, Craig AM, Pavlidis P.
598 Transcriptomic correlates of electrophysiological and morphological diversity within and
599 across excitatory and inhibitory neuron classes. PLoS Comput Biol. 2019
600 Jun;15(6):e1007113.
- 601 51. Basel-Vanagaite L, Attia R, Yahav M, Ferland RJ, Anteki L, Walsh CA, et al. The CC2D1A,
602 a member of a new gene family with C2 domains, is involved in autosomal recessive non-
603 syndromic mental retardation. J Med Genet. 2006 Mar;43(3):203–10.
- 604 52. Perez Y, Menascu S, Cohen I, Kadir R, Basha O, Shorer Z, et al. RSRC1 mutation affects
605 intellect and behaviour through aberrant splicing and transcription, downregulating IGFBP3.
606 Brain J Neurol. 2018 Apr 1;141(4):961–70.
- 607 53. Maddirevula S, AlZahrani F, Anazi S, Almureikhi M, Ben-Omran T, Abdel-Salam GMH, et
608 al. GWAS signals revisited using human knockouts. Genet Med Off J Am Coll Med Genet.
609 2018 Jan;20(1):64–8.
- 610 54. Nabais Sá MJ, Jensik PJ, McGee SR, Parker MJ, Lahiri N, McNeil EP, et al. De novo and
611 biallelic DEAF1 variants cause a phenotypic spectrum. Genet Med Off J Am Coll Med
612 Genet. 2019 Sep;21(9):2059–69.
- 613 55. Manzini MC, Xiong L, Shaheen R, Tambunan DE, Di Costanzo S, Mitisalis V, et al.
614 CC2D1A regulates human intellectual and social function as well as NF-κB signaling
615 homeostasis. Cell Rep. 2014 Aug 7;8(3):647–55.
- 616 56. Douzgou S, Petersen MB. Clinical variability of genetic isolates of Cohen syndrome. Clin
617 Genet. 2011 Jun;79(6):501–6.

Biallelic variants for autism....

- 618 57. Rajab A, Schuelke M, Gill E, Zwirner A, Seifert F, Morales Gonzalez S, et al. Recessive
619 DEAF1 mutation associates with autism, intellectual disability, basal ganglia dysfunction
620 and epilepsy. *J Med Genet.* 2015 Sep;52(9):607–11.
- 621 58. Smith DR, Stanley CM, Foss T, Boles RG, McKernan K. Rare genetic variants in the
622 endocannabinoid system genes CNR1 and DAGLA are associated with neurological
623 phenotypes in humans. *PloS One.* 2017;12(11):e0187926.
- 624 59. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, et al. De novo
625 mutations revealed by whole-exome sequencing are strongly associated with autism. *Nature.*
626 2012 Apr 4;485(7397):237–41.
- 627 60. Pillai NR, Yubero D, Shayota BJ, Oyarzábal A, Ghosh R, Sun Q, et al. Loss of CLTRN
628 function produces a neuropsychiatric disorder and a biochemical phenotype that mimics
629 Hartnup disease. *Am J Med Genet A.* 2019 Dec;179(12):2459–68.
- 630 61. Berciano J, García A, Gallardo E, Peeters K, Pelayo-Negro AL, Álvarez-Paradelo S, et al.
631 Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and
632 systematic review. *J Neurol.* 2017 Aug;264(8):1655–77.
- 633 62. Mirzaa GM, Chong JX, Piton A, Popp B, Foss K, Guo H, et al. De novo and inherited
634 variants in ZNF292 underlie a neurodevelopmental disorder with features of autism spectrum
635 disorder. *Genet Med.* 2020 Mar;22(3):538–46.
- 636 63. Sener EF, Onal MG, Dal F, Nalbantoglu U, Ozkul Y, Canatan H, et al. Novel alterations of
637 CC2D1A as a candidate gene in a Turkish sample of patients with autism spectrum disorder.
638 *Int J Neurosci.* 2020 Dec 28;1–8.
- 639 64. Wu J, Yu P, Jin X, Xu X, Li J, Li Z, et al. Genomic landscapes of Chinese sporadic autism
640 spectrum disorders revealed by whole-genome sequencing. *J Genet Genomics Yi Chuan Xue*
641 *Bao.* 2018 Oct 20;45(10):527–38.
- 642 65. Guo H, Wang T, Wu H, Long M, Coe BP, Li H, et al. Inherited and multiple de novo
643 mutations in autism/developmental delay risk genes suggest a multifactorial model. *Mol*
644 *Autism.* 2018;9:64.
- 645 66. Wang T, Guo H, Xiong B, Stessman HAF, Wu H, Coe BP, et al. De novo genic mutations
646 among a Chinese autism spectrum disorder cohort. *Nat Commun.* 2016 Nov 8;7:13316.
- 647 67. Coursimault J, Guerrot AM, Morrow MM, Schramm C, Zamora FM, Shanmugham A, et al.
648 MYT1L-associated neurodevelopmental disorder: description of 40 new cases and literature
649 review of clinical and molecular aspects. *Hum Genet.* 2021 Nov 8;
- 650 68. Weiss LA, Escayg A, Kearney JA, Trudeau M, MacDonald BT, Mori M, et al. Sodium
651 channels SCN1A, SCN2A and SCN3A in familial autism. *Mol Psychiatry.* 2003
652 Feb;8(2):186–94.

Biallelic variants for autism....

- 653 69. Jiang Y hui, Yuen RKC, Jin X, Wang M, Chen N, Wu X, et al. Detection of clinically
654 relevant genetic variants in autism spectrum disorder by whole-genome sequencing. *Am J*
655 *Hum Genet.* 2013 Aug 8;93(2):249–63.
- 656 70. Faber CG, Lauria G, Merkies ISJ, Cheng X, Han C, Ahn HS, et al. Gain-of-function Nav1.8
657 mutations in painful neuropathy. *Proc Natl Acad Sci U S A.* 2012 Nov 20;109(47):19444–9.
- 658 71. Bebbington A, Percy A, Christodoulou J, Ravine D, Ho G, Jacoby P, et al. Updating the
659 profile of C-terminal MECP2 deletions in Rett syndrome. *J Med Genet.* 2010
660 Apr;47(4):242–8.
- 661 72. Neuser S, Brechmann B, Heimer G, Brösse I, Schubert S, O’Grady L, et al. Clinical,
662 neuroimaging, and molecular spectrum of TECPR2-associated hereditary sensory and
663 autonomic neuropathy with intellectual disability. *Hum Mutat.* 2021 Jun;42(6):762–76.
- 664 73. Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification of childhood
665 autism: Childhood Autism Rating Scale (CARS). *J Autism Dev Disord.* 1980 Mar;10(1):91–
666 103.
- 667 74. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of
668 a diagnostic interview for caregivers of individuals with possible pervasive developmental
669 disorders. *J Autism Dev Disord.* 1994 Oct;24(5):659–85.
- 670 75. Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, et al. Autism diagnostic
671 observation schedule: a standardized observation of communicative and social behavior. *J*
672 *Autism Dev Disord.* 1989 Jun;19(2):185–212.
- 673 76. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders,*
674 *4th Edition, Text Revision.* 4th edition. Washington, DC: American Psychiatric Association;
675 2000. 943 p.
- 676 77. Skuse D, Warrington R, Bishop D, Chowdhury U, Lau J, Mandy W, et al. The
677 developmental, dimensional and diagnostic interview (3di): a novel computerized assessment
678 for autism spectrum disorders. *J Am Acad Child Adolesc Psychiatry.* 2004 May;43(5):548–
679 58.
- 680 78. American Psychiatric Association, American Psychiatric Association, DSM-5 Task Force.
681 *Diagnostic and statistical manual of mental disorders: DSM-5.* [Internet]. 2013 [cited 2016
682 Dec 14]. Available from: <http://dsm.psychiatryonline.org/book.aspx?bookid=556>
- 683 79. World Health Organization. *The ICD-10 Classification of Mental and Behavioural Disorders*
684 [Internet]. World Health Organization; 2010. Available from:
685 <https://www.who.int/classifications/icd/en/bluebook.pdf>
- 686 80. Packer JS, Maxwell EK, O’Dushlaine C, Lopez AE, Dewey FE, Chernomorsky R, et al.
687 CLAMMS: a scalable algorithm for calling common and rare copy number variants from
688 exome sequencing data. *Bioinformatics.* 2016 Jan 1;32(1):133–5.

689

Biallelic variants for autism....

690

691 **Table 1:** Cohort Description and clinical assessment.

| Cohort ID (Recruited By) | Institute | Nationality (Age range) | Number of Trios (Number of DNAs) | Proband Male: Female | Instruments and diagnostic system | Assessors |
|--|--|--------------------------------|---|-----------------------------|--|---|
| SMPA (Ansa Rabia, Saqib Mahmood, Shazia Maqbool) | University of Health Sciences and Children Hospital, Lahore | Pakistan | 54 (162) | 42:12 | Childhood Autism Rating Scale (CARS)(73) DSM IV | Physicians with expertise in neurodevelopmental disorders |
| IAU (Dr. Sasanfar) | Children’s Health and Evaluation Project/ Special Education Organization | Iran (4-11) | 27 (81) | 23:4 | ADI-R (74) and ADOS (75) (DSM-IV-TR) (76); SCQ (50) | Certified Physicians |
| IABB (Dr. Bita Bozorgmehr) | Shahid Beheshti Medical University, Teheran | Iran | 10 (30) | 9:2 | Autism Spectrum Screening Questionnaire (ref) DSM IV | Dr. Bita Bozorgmehr |
| SA (Laila Al Ayadhi) | Autism Treatment Centre, King Saud University, Riyadh | Saudi Arabia (2-12) | 13 (39) | 12:1 | ADI-R (74), Autism Diagnostic Observation Schedule (ADOS) (75) and 3DI (Developmental, dimensional diagnostic interview) scales (77) Childhood Autism Rating Scale (CARS)(73); DSM IV | Laila Al Ayadhi |
| Autism (Raheel Qamar, Maleeha Azam and Zehra Agha) | COMSATS University, Islamabad, and National Rural Support Program | Pakistan | 4 (12) | 4:4 | Childhood Autism Rating Scale (CARS)(73) | Who? |

Biallelic variants for autism....

| | | | | | | |
|--|---------------------------------------|------|-----------|-------|-------------------------------------|-------------------------|
| RQPA (Raheel Qamar, Maleeha Azam and Zehra Agha) | and the Ghazi Barotha Taraqiata iDara | | 4 (12) | | DSM-5 (78) and ICD-10 criteria (79) | Who? |
| IAH (Abolfazl Heidari) | Qazvin Medical University, Qazvin | Iran | 3 (9) | 2:1 | DSM IV | Dr Hossein Mojdehipanah |
| Total | | | 115 (345) | 91:24 | | |

692

693

Biallelic variants for autism....

694 **Table 2: Biallelic/homozygous variants:** Genes previously reported as pathogenic for ASD/ID or other disorder are indicated, with
 695 annotation using (in order of priority): OMIM: <https://omim.org/>; SFARI ASD genes <https://gene.sfari.org/>; DDD gene2phenotype
 696 genes: <https://www.ebi.ac.uk/gene2phenotype/>; Geisinger developmental brain disorder gene database:
 697 <https://dbd.geisingeradmi.org/>; NPdenovo: <http://www.wzgenomics.cn/NPdenovo/>; Gene4denovo:
 698 <http://www.genemed.tech/gene4denovo/search>. Genes previously unreported for ASD or ID are in bold type. Control population
 699 frequencies show are from gnomAD (all, and for South Asian sub-population). All variants were validated by IGV (Integrated
 700 Genomics Viewer; Broad Institute) and by Sanger sequencing. Validations are shown in Supplementary Materials. Allele frequencies
 701 are from gnomAD v2.1.1 (www. <https://gnomad.broadinstitute.org/>; accessed June 2022).

| Variant | Family | Chr | Coordinates (hg19) | Ref. | Alt. | Gene | Variant Type | cDNA/Amino Acid Change | gnomAD All Freq. | gnomAD S. Asian Freq. |
|---------|---------|-----|---------------------|-----------|------|--|----------------|---|------------------|-----------------------|
| 1 | SMPA3 | 1 | 11855404 | C | A | MTHFR (29)(MIM 236250; SFARI score 2) | nonsynonymous | NM_001330358.2: exon6: c. 905G>T: p. Gly302Val | 3.99E-06 | 3.27E-05 |
| 2 | IABB16 | 1 | 87029377 | G | A | CLCA4 | nonsynonymous | NM_012128.3:c.482G>A:p.Arg161Gln | 4.11E-04 | 1.72E-03 |
| 3 | SMPA4 | 1 | 152193673-152193682 | GACGTTCTG | - | HRNR | frameshift del | NM_001009931.3: exon3: c.423_432del:p.Arg142Glufs*15 | 4.37E-05 | 3.59E-4 |
| 4 | SMPA76 | 1 | 166891855-166891856 | CT | - | ILDR2 | frameshift del | NM_199351.3: exon8: c.1187_1188del: p. Glu396Glyfs*39 | 3.98E-06 | 3.27E-05 |
| 5 | SMPA3 | 1 | 178425880 | C | A | RASAL2 | Nonsynonymous | NM_004841.3: exon11: c.1813C>A: p. Leu605Ile | 6.72E-4 | 6.04E-3 |
| 6 | SMPA40 | 1 | 197621364 | C | A | DENND1B | Splicing | NM_001195215.1: exon7: c.447+1G>T | 0 | 0 |
| 7 | Autism8 | 2 | 74759786 | G | T | HTRA2 (MIM 617248) | Nonsynonymous | NM_013247.3: exon7: c.1156G>T: p. Asp386Tyr | 7.95E-06 | 6.53E-05 |
| 8 | SMPA19 | 3 | 38802185 | C | A | SCN10A | Stopgain | NM_001293306.2: exon7: c.937G>T; p. Gly313* | 3.98E-06 | 3.27E-05 |
| 9 | SMPA76 | 3 | 43593070 | C | A | ANO10 (spinocerebellar ataxia 10, MIM 613728) | Nonsynonymous | NM_001346463.2:exon11:c.1679G>T:p.Cys560Phe | 0 | 0 |
| 10 | SA15 | 3 | 47164429 | G | C | SETD2 (LLS (AD) MIM 616831; SFARI score 1; Geisinger Tier 1) | Nonsynonymous | NM_001349370.3: exon2:c.1565C>G: p. Ser522Cys | 0 | 0 |

Biallelic variants for autism....

| | | | | | | | | | | |
|----|---------|----|-----------|-----|------|---|----------------|--|----------|-----------|
| 11 | SMPA27 | 3 | 134911657 | T | C | EPHB1 (SFARI score 3) | Nonsynonymous | NM_004441.3: exon11: c.2122T>C: p. Phe708Lys | 4.01E-06 | 3.27E-05 |
| 12 | Autism3 | 3 | 157840002 | C | T | RSRC1 (MRT70; MIM 618402; SFARI score 5) | Stopgain | NM_001271834.2: exon2:c.109C>T: p. Arg37* | 0 | 0 |
| 13 | SMPA8 | 3 | 169524635 | C | T | LRR34 | Splicing | NM_001172779.1: exon5: c.528+1G>A | 4.08E-06 | 03.44E-05 |
| 14 | SMPA40 | 4 | 111480831 | C | T | ENPEP | Stop gain | NM_001977.4: exon19: c.2671C>T; p.Arg891* | 1.791E-4 | 1.34E-03 |
| 15 | RQPA12 | 4 | 178360822 | G | A | AGA (MIM 208400) | Nonsynonymous | NM_000027.3: exon3: c.302C>T: p. Ala101Val | 3.98E-06 | 3.27E-05 |
| 16 | SMPA35 | 4 | 185033930 | CAT | C | ENPP6 | frameshift del | NM_153343.3: exon6: c.886_887del: p.Met296Aspfs*28 | 0 | 0 |
| 17 | IABB11 | 5 | 35910583 | C | T | CAPSL | Nonsynonymous | NM_144647.3:c.200G>A:p.Gly67Glu | 0 | 0 |
| 18 | Autism8 | 5 | 150846823 | - | CTGG | SLC36A1 | frameshift ins | NM_001308150.2: exon6:c.487_490dup: p. Asp164Glyfs*2 | 8.01E-06 | 6.6E-05 |
| 19 | IAU56 | 5 | 154199963 | C | - | FAXDC2 | frameshift del | NM_032385.3: exon9: c.915delG: p.Thr306Profs*100 | 5.28E-05 | 3.93E-04 |
| 20 | SMPA48 | 6 | 13634723 | C | G | RANBP9 | Nonsynonymous | NM_005493.3: exon11: c.1735G>C: p. Gly579Arg | 2.89E-05 | 1.06E-04 |
| 21 | IABB8 | 6 | 38851674 | A | T | DNAH8 | Nonsynonymous | NM_001206927.2: exon56: c.8159A>T: p. Asp2720Val | 1.24E-05 | 1.02E-04 |
| 22 | IAU7 | 7 | 47944924 | T | C | PKD1L1 (AR laterality defects; MIM 616205) | Splicing | NM_138295.3: exon11: c.1523-2A>G | 0 | 0 |
| 23 | SA7 | 7 | 65551627 | C | T | ASL (MIM 207900)# | Nonsynonymous | NM_001024943.2: exon6:c.502C>T: p. Arg168Cys | 7.98E-06 | 0 |
| 24 | IABB7 | 7 | 99720009 | G | C | CNPY4 | Splicing | NM_152755.1: exon2: c.245+1G>C | 2.12E-05 | 0 |
| 25 | IAU79 | 7 | 150174821 | TCC | T | GIMAP8 | frameshift del | NM_175571.3: exon5: c.1952_1953del: p. Gln652Serfs*6 | 0 | 0 |
| 26 | SMPA11 | 7 | 155604611 | T | A | SHH (HPE3 (AD) MIM 142945) | Nonsynonymous | NM_000193.4: exon1: c.206A>T: p. Asn69Ile | 2.39E-06 | 1.96E-4 |
| 27 | IABB3 | 8 | 100155379 | AG | A | VPS13B (COH1 MIM 216550; SFARI score 1; Geisinger AR) | frameshift del | NM_015243.3: exon13: c.1829delG: p. Ser610Thrfs*3 | 0 | 0 |
| 28 | SA4 | 9 | 5805613 | T | C | ERMP1 | Nonsynonymous | NM_024896.3: exon9: c.1721A>G: p.His574Arg | 0 | 0 |
| 29 | IABB2 | 11 | 679701 | G | GA | DEAF1 (MIM 617171; SFARI score 1; Geisinger AR) | frameshift ins | NM_001293634.1: exon6: c.845dupT: p. Ala283Argfs*20 | 0 | 0 |

Biallelic variants for autism....

| | | | | | | | | | | |
|----|--------|----|-------------------|----------------------------|---|--|-------------------|---|-----------|----------|
| 30 | SMPA11 | 11 | 6477889 | C | A | TRIM3 | Nonsynonymous | NM_033278.3:exon6:c.1067G>T:p.Arg356Leu | 0 | 0 |
| 31 | SMPA20 | 11 | 47305749 | A | G | MADD (27,30) | Nonsynonymous | NM_001135943.2: exon11: c. 1883A>G: p. Tyr628Cys | 1.99E-05 | 1.63E-04 |
| 32 | SMPA21 | 11 | 61495635 | C | G | DAGLA (SFARI score 2) | Stopgain | NM_006133.3: exon7:c.647C>G: p. Ser216* | 0 | 0 |
| 33 | SMPA80 | 11 | 67290028 | C | T | CABP2 (Deafness, MIM 607314) | Nonsynonymous | NM_016366.3: exon2: c.202G>A: p. Ala68Thr | 5.70E-05 | 3.48E-04 |
| 34 | SMPA8 | 11 | 118403863 | A | G | TMEM25 | Nonsynonymous | NM_001144036.2: exon3: c. 302A>G: p. Asn101Ser | 3.64E-05 | 2.62E-04 |
| 35 | IAU79 | 12 | 58021514_58021534 | GGGAAGCCGAC GAGCTCGTGGT | G | B4GALNT1 (Spastic paraplegia 26; MIM 609195 ID reported in some cases) | nonframeshift del | NM_001276468.2: exon9: c.1094_1114del: p.His365_Phe372del | 0 | 0 |
| 36 | IABB10 | 12 | 69263140 | C | G | CPM | Nonsynonymous | NM_001005502.2: exon6: c.752G>C: p. Gly251Ala | 0 | 0 |
| 37 | IABB11 | 12 | 118199039 | G | A | KSR2 | Nonsynonymous | NM_173598.6:exon4:c.763C>T:p.Arg255Trp | 2.196E-05 | 0 |
| 38 | SMPA8 | 14 | 65032074 | G | C | PPP1R36 | Splicing | NM_172365: exon5: c.270-1G>C | 1.21E-05 | 9.99E-05 |
| 39 | IAH2 | 14 | 102963429 | TGTGGGGACCGCT CTG | | TECPR2 Anazi et al, 2017 PMID 27431290); Neuropathy, hereditary sensory and autonomic, type IX, with developmental delay (HSAN9): MIM 615031 | frameshift del | NM_014844.3: exon18: c.3904_3917del: p. Val1302Glyfs*60 | 0 | 0 |
| 40 | IABB4 | 15 | 101113962 | T | - | LINS1 (MRT27; MIM 614340; Geisinger AR) | frameshift del | NM_001040616.3: exon5: c.1116delA: p. Glu372Aspfs*9 | 0 | 0 |
| 41 | SMPA76 | 16 | 716004 | C | T | WDR90 | Nonsynonymous | NM_145294.4: exon36: c.4489C>T: p. Arg1497Trp | 3.72E-06 | 8.04E-06 |
| 42 | IABB14 | 17 | 3392637 | G | T | ASPA (Canavan disease; MIM 271900) | Splicing | NM_001128085: exon5: c.634+1G>T | 1.06E-05 | 3.28E-05 |
| 43 | SA2 | 19 | 14024452 | G | T | CC2D1A (MRT3; MIM 608443; SFARI score 2; Geisinger AR) | Splicing | NM_017721: exon6: c.748+1G>T | 0 | 0 |
| 44 | IABB16 | 19 | 50321659 | G | A | MED25 (BVFYS; MIM 616449) | Nonsynonymous | NM_030973.3: exon1: c.61G>A: p. Val21Met | 0 | 0 |

Biallelic variants for autism....

| | | | | | | | | | | |
|----|--------|----|----------|---|---|--|----------------|---|----------|----------|
| 45 | SA11 | 19 | 58265432 | C | - | ZNF766 | Frameshift del | NM_173632.4:c.934delC: p.Arg312Glufs*80 | 3.266E-5 | 1.55E-5 |
| 46 | IABB16 | 20 | 2847201 | C | A | VPS16 (Dystonia (AD) MIM 619291) | Nonsynonymous | NM_080413.3: exon20: c.2069C>A: p. Ala690Glu | 1.99E-05 | 6.53E-05 |
| 47 | IABB16 | 20 | 16360737 | A | G | KIF16B (PMID 29736960) | Nonsynonymous | NM_001199865.2: exon19: c. T1910T>C: p. Val637Ala | 0 | 0 |
| 48 | IABB5 | 20 | 44578999 | C | T | ZNF335 Hu et al, 2019; MCPH10; MIM 615095; Geisinger Tier 4) | Nonsynonymous | NM_022095.3: exon22: c.3346G>A: p. Gly1116Arg | 1.26E-5 | 0 |
| 49 | IABB11 | 22 | 40803252 | G | C | SGSM3 (SFARI score 2; Geisinger Tier 4) | Nonsynonymous | NM_001350039.2:c.1288G>C:p.Glu430Gln | 1.99E-5 | 1.63E-4 |

702 # SpliceAI predicts the generation of a splice donor site.

703

Biallelic variants for autism....

704 **Table 3: De novo variants.** Genes previously reported as pathogenic for ASD/ID or other disorder are indicated, with annotation
 705 using (in order of priority): OMIM: <https://omim.org/>; SFARI ASD genes <https://gene.sfari.org/>; DDD gene2phenotype genes:
 706 <https://www.ebi.ac.uk/gene2phenotype/>; Geisinger developmental brain disorder gene database: <https://dbd.geisingeradmi.org/>;
 707 NPdenovo: <http://www.wzgenomics.cn/NPdenovo/>; Gene4denovo: <http://www.genemed.tech/gene4denovo/search>. Genes
 708 previously unreported for ASD or ID are in bold type. Control population frequencies shown are from gnomAD (all, and for South
 709 Asian sub-population). Allele frequencies are from gnomAD v2.1.1 (www. <https://gnomad.broadinstitute.org/>; accessed June 2022).
 710 All variants were validated by IGV (Integrated Genomics Viewer; Broad Institute) and by Sanger sequencing. Validations are shown in
 711 Supplementary Materials.

| Variant | Family | Chr | Coordinates (hg19) | Ref. | Alt. | Gene (previously reported) | Variant Type | cDNA/Amino Acid Change | gnomAD All Freq. | gnomAD S. Asian Freq. |
|---------|--------|-----|--------------------|------|------|---|----------------|---|------------------|-----------------------|
| 1 | RQPA20 | 1 | 28919246 | G | A | RAB42 | nonsynonymous | NM_001193532.3: exon1: c. 223G>A: p. Glu75Lys | 0 | 0 |
| 2 | RQPA20 | 1 | 112031311 | A | - | TMIGD3 | frameshift del | NM_001302680.2: exon2: c.286delT: p. Trp96Glyfs*36 | 0 | 0 |
| 3 | RQPA20 | 1 | 150483966 | G | T | ECM1 (DDD G2P: lipoid proteinosis, AR) | Stopgain | NM_001202858.2: exon7: c.823G>T: p. Glu275* | 7.96E-06 | 6.53E-05 |
| 4 | RQPA20 | 1 | 160722912 | C | A | SLAMF7 | Stopgain | NM_001282589.2: exon5:c.560C>A: p. Ser187* | 0 | 0 |
| 5 | IAU29 | 2 | 1946866 | C | - | MYT1L (MRD39: MIM 616521; SFARI score 1; MYT1L) | frameshift del | NM_001303052.2: exon9: c.394delG: p. Glu132Argfs*42 | 0 | 0 |
| 6 | SMPA53 | 2 | 166166958 | C | T | SCN2A (DEE11: MIM 6137219; SFARI score 1; Geisinger Tier 1) | Stopgain | NM_001040143.2: exon6:c.823C>T: p. Arg275* | 3.98E-06 | 4.62E-05 |
| 7 | SMPA38 | 2 | 166201156 | C | A | SCN2A (DEE11: MIM 6137219; SFARI score 1; Geisinger Tier 1) | Nonsynonymous | NM_001040143.2:exon15:c.2654C>A:p.Thr885Asn | 0 | 0 |

Biallelic variants for autism....

| | | | | | | | | | | |
|----|----------|----|-------------------|----|---|---|----------------|--|----------|----------|
| 8 | IAU66 | 2 | 232320177 | C | - | NCL | frameshift del | NM_005381: exon13: c.1991delG: p. Gly664Glufs*70 | 0 | 0 |
| 9 | SA1 | 3 | 38645393 | A | T | SCN5A (BRGDA1: MIM 601144) | Nonsynonymous | NM_198056.3:exon12:c.1700T>A: p. Leu567Gln | 8.031E-6 | 0 |
| 10 | SMPA75 | 5 | 137680632 | - | T | FAM53C | frameshift ins | NM_001135647.2: exon4: c.256dupT: p. Ser86Phefs*14 | 0 | 0 |
| 11 | SMPA75 | 6 | 47646871 | G | A | ADGRF2 | Splicing | NM_153839.7: exon5: c.267+1G>A | 4.01E-06 | 3.27E-05 |
| 12 | Autism10 | 6 | 87969507-87969508 | AG | - | ZNF292 (MRD64: MIM 619188; SFARI score 1; Geisinger Tier 1) | frameshift del | NM_015021.3: exon8: c.6159_6160del: p. Glu2054Lysfs*14 | 0 | 0 |
| 13 | IAU65 | 6 | 87969506-87969507 | AG | - | ZNF292 (MRD64: MIM 619188; SFARI score 1; Geisinger Tier 1) | frameshift del | NM_015021.3: exon8: c.6159_6160del: p. Glu2054Lysfs*14 | 0 | 0 |
| 14 | RQPA20 | 11 | 46389550 | A | C | DGKZ | Splicing | NM_201533: exon4: c.379-2A>C | 0 | 0 |
| 15 | Autism9 | 12 | 52188238 | G | A | SCN8A (DEE13: MIM 614558; SFARI score 1) | Nonsynonymous | NM_014191.4:c.4608G>A: p. Met1536Ile | 0 | 0 |
| 16 | SMPA73 | 12 | 89998008 | G | C | ATP2B1 (MRD66: MIM 619910; SFARI score 3S) | Stopgain | NM_001001323.2: exon15:c.2558C>G: p. Ser853* | 0 | 0 |
| 17 | RQPA20 | 16 | 89006655 | G | A | LOC100129697/CBFA2T3 | Nonsynonymous | NM_001290330.2: exon1: c.53G>A: p. Arg18Lys | 0 | 0 |
| 18 | SMPA75 | 19 | 7734220-7734221 | CT | - | RETN | frameshift del | NM_001193374.1: exon2: c.8_9del: p. Cys5Serfs*13 | 4.37E-05 | 3.27E-04 |
| 19 | RQPA20 | 22 | 20049060 | C | G | TANGO2 (Geisinger AR) | Stop gain | NM_152906.7:exon7:c.459C>G: p. Tyr153* | 0 | 0 |
| 20 | RQPA20 | 22 | 22051034 | A | G | PPIL2 | Splicing | NM_148175: exon21: c.1570-2A>G | 0 | 0 |

Biallelic variants for autism....

713 **Table 4: X-linked variants.** Genes previously reported as pathogenic for ASD/ID or other disorder are indicated, with annotation
 714 using (in order of priority): OMIM: <https://omim.org/>; SFARI ASD genes <https://gene.sfari.org/>; DDD gene2phenotype genes:
 715 <https://www.ebi.ac.uk/gene2phenotype/>; Geisinger developmental brain disorder gene database: <https://dbd.geisingeradmi.org/>;
 716 NPdenovo: <http://www.wzgenomics.cn/NPdenovo/>; Gene4denovo: <http://www.genemed.tech/gene4denovo/search>. Genes
 717 previously unreported for ASD or ID are in bold type. Control population frequencies shown are from gnomAD (all, and for South
 718 Asian sub-population). Allele frequencies are from gnomAD v2.1.1 (www. <https://gnomad.broadinstitute.org/>; accessed June 2022).
 719 All variants were validated by IGV (Integrated Genomics Viewer; Broad Institute) and by Sanger sequencing. Validations are shown in
 720 Supplementary Materials.

| Variant | Family | Mode of Inheritance | Coordinates (hg19) | Ref | Alt | Gene (previous reports) | Variant Type | cDNA/Amino Acid Change | gnomAD All Freq. | gnomAD S. Asian Freq. |
|---------|--------|---------------------|--------------------|-----|-----|---------------------------|----------------|---|------------------|-----------------------|
| 1 | SMPA3 | Recessive | 30236780 | C | - | MAGEB2 | frameshift del | NM_002364.4:c.83delC:p.Pro28Leufs*84 | 0 | 0 |
| 2 | IAU66 | Recessive | 48672948 | A | G | HDAC6 | Nonsynonymous | NM_006044.4:c.908A>G: p.Tyr303Cys | 0 | 0 |
| 3 | IAU69 | Recessive | 55779942 | T | C | RRAGB | Nonsynonymous | NM_006064.4: exon7: c.730T>C: p. Phe244Leu | 5.49E-06 | 1.23E-05 |
| 4 | IAU45 | Recessive | 64947718 | C | A | MSN | Nonsynonymous | NM_002444.3: exon3: c.139C>A: p. Leu47Met | 0 | 0 |
| 5 | SMPA15 | Recessive | 105193588 | C | T | NRK | Stopgain | NM_198465.4: exon27: c.4375C>T: p. Gln1459* | 0 | 0 |
| 6 | IAU47 | Recessive | 107170098 | A | G | MID2 (MRX101; MIM 300928) | nonsynonymous | NM_012216.4:c.2003A>G:p.Tyr668Cys | 0 | 0 |
| 7 | IAU24 | Recessive | 129290446 | C | T | AIFM1 (Cowchock | nonsynonymous | NM_001130847.4: exon2: c. 238G>A: p. Ala80Thr | 0 | 0 |

Biallelic variants for autism....

| | | | | | | | | | | |
|----|--------|-----------|-----------|---|---|---|-----------------|--|----------|---|
| | | | | | | syndr.; MIM 310490) | | | | |
| 8 | IAU51 | Recessive | 140994661 | - | A | MAGEC1 | frameshift ins | NM_005462.3:c.1471_1472insA; p.Leu491Tyrfs*10 | 4.37E-05 | 0 |
| 9 | IABB8 | Recessive | 152106616 | A | G | ZNF185 | Splicing | NM_001178110: exon13: c.942-2A>G | 0 | 0 |
| 10 | SA1 | De Novo | 15677205 | T | A | CLTRN (TMEM27) | nonsynonymous & | NM_020665.3:exon3:c.137A>T:p.Glu46Val | 0 | 0 |
| 11 | SMPA71 | De Novo | 62926209 | G | A | ARHGEF9 (DEE8; MIM 300607; SFARI score 1S; Geisinger Tier1) | nonsynonymous | NM_015185.3: exon3:c.310C>T: p.Arg104Trp | 0 | 0 |
| 12 | SMPA84 | De Novo | 100507601 | A | C | DRP2 (CMTX1 MIM 302800; PMID 26227883) | nonsynonymous | NM_001171184.2: exon15: c. 1639A>C: p. Ser547Arg | 0 | 0 |
| 13 | IAU54 | De Novo | 153296081 | - | T | MECP2 (RTT; MIM 312750; SFARI score 1; Geisinger Tier1) | frameshift ins | NM_001110792.2:exon3:c.1234dup:p.Th r412Asnfs*5 | 0 | 0 |
| 14 | SMPA78 | De Novo | 153296516 | G | A | MECP2 (RTT; MIM 312750; SFARI score 1' Geisinger Tier1) | Stopgain | NM_001110792.2:exon3:c.799C>T:p. Arg267* | 0 | 0 |

721 &MutationTaster predicts splice donor created

722

Biallelic variants for autism....

723 **Table 5: CNV summary:** validated biallelic loss CNVs called by CNVpartition or ChAS. Biallelic losses called from microarray data by
 724 PennCNV and from WES data by CLAMMS (80)) did not validate using IGV, and hence are not included. Comparison with control
 725 population CNVs used the Database of Genomic Variants (DGV) Gold, accessed through the Decipher genomic browser
 726 (www.deciphergenomics.org), also through gnomAD. Coordinates given using hg19.

| Family | Mode of Inheritance | (hg19) | Cytoband | Size (Kb) | CN | CNV confidence | Genes | FREQ IN DGV GOLD STANDARD, gnomAD, or rare? | IGV | PCR |
|--------|---------------------|---------------------------|----------|-----------|----|----------------|--|---|-----|-----|
| SMPA4 | Recessive | 14:24,454,924-24,464,325 | 14q11.2 | 9.402 | 0 | 345.9659 | DHRS4 exon 8; DHRS4L2 exons 1-4 | Partial overlap with gssvL33876 FREQ 0.0029 | Y | Y |
| SMPA4 | Recessive | 20: 43836785-43836964 | 20q13.12 | 0.18 | 0 | 228.5597 | SEMG1 exon 2, 180bp, 60 amino acids | Partial overlap with gssvL72784 FREQ 0.0038 | Y | Y |
| SMPA8 | Recessive | 2:196,799,394-196,801,362 | 2q32.3 | 1.969 | 0 | 139.6294 | DNAH7 exon 20-21 | NONE | Y | Y |
| SMPA3 | Recessive | 5:140,224,038-140,242,319 | 5q31.3 | 18.282 | 0 | 1417.866 | PCDHA9, PCDHA10 (SFARI score 2) | Also Hom in mother | Y | Y |
| IAH2 | Recessive | 5:140,224,038-140,242,319 | 5q31.3 | 18.282 | 0 | 1417.866 | PCDHA9, PCDHA10 (SFARI score 2) | Also Hom in father | Y | Y |
| IAU79 | Recessive | 20:1,559,259-1,559,330 | 20p13 | 0.072 | 0 | 171.6751 | SIRPB1 exon 2 | Partial OVERLAP WITH COMMON CNV (0.0894) | Y | Y |
| IABB2 | Recessive | 17:3513856- 3514054 | 17p13.2 | 0.198 | 0 | 318.3258 | SHPK exon 7 | Partial OVERLAP WITH 80Kb gssvL47583 (0.00274) | Y | Y |
| IABB14 | Recessive | 15:85186877-85186894 | 15q25.2 | 0.018 | 0 | 55.68398 | WDR73 exon 8 ^s | rs760394400; gnomAD MAF 0.1672 | Y | Y |
| IABB14 | Recessive | 19:41356319-41386033 | 19q13.2 | 29.714 | 0 | 579.0146 | CYP2A7 6 exons | gssvL58578 0.002 Plus gssvL58575 0.0017 | Y | Y |

Biallelic variants for autism....

| | | | | | | | | | | |
|--------|-----------|-----------------------|----------|--------|---|----------|--------------|---|---|---|
| IABB14 | Recessive | 19: 51330951-51331063 | 19q13.33 | 0.112 | 0 | 579.0146 | KLK15 exon 2 | Overlap with gssvL59230 0.02 | Y | Y |
| SMPA42 | X-linked | X:47912041-47970683 | Xp11.23 | 58.643 | 0 | 1665.299 | ZNF630; SSX6 | Deletions in ZNF630 do not segregate with ID; PMID 20186789 | Y | |
| SMPA9 | X-linked | X:47917867-47970683 | Xp11.23 | 52.817 | 0 | 1558.271 | ZNF630; SSX6 | Ditto | Y | |

727 \$ see Riazuddin et al, 2017; PMID_30171209)

Biallelic variants for autism....

728 **Figure Legends**

729 **Figure 1: Variant prioritization methods where variants that pass GATK best practices would**
730 **be filtered for MAF less than or equal to 10^{-4} and then categorized into recessive or**
731 **homozygous variants.** Variants are then prioritized based on assessment of potential damage
732 to the protein, and then filtered based on scoring algorithms to predict pathogenicity.

733


734 **Figure 2: Violin plots comparing consanguinity coefficient F_{roh} , for A:** different categories of
735 variant identified: All biallelic variants (N=27 observations), variants in known AR ID and/or ASD
736 genes (N=10 observations), variants in novel candidate genes (N=17 observations), all X-linked
737 (XL) variants plus *de novo* autosomal dominant (AD) variants (N=18 observations), variants in
738 known XL and AD genes (N=11 observations), and variants in novel candidate XL and AD genes
739 (N=7 observations). Unpaired *t* test (2-tailed) for comparison of means showed comparison for
740 i) all biallelic versus all *de novo* autosomal plus X-linked to be extremely significant ($p < 0.0001$,
741 $t = 5.8309$, d.f.=51), ii) known AR versus AD ID and/or ASD genes to be strongly significant
742 ($p = 0.0045$, $t = 3.1642$, d.f.=22), iii) novel candidate AR versus AD genes to be strongly significant
743 ($p < 0.0001$, $t = 5.4795$, d.f.=26). No significant difference in mean F_{roh} was seen for comparisons
744 between known and novel candidate AR genes, or between known and novel AD plus XL genes;
745 **B:** different cohorts, categorized by last name of principal investigator for each collection (Agha,
746 N=3, Ansar, N=52, Heidari, N=2, Al Ayadhi, N=13, Bozorgmehr, N=10, Sasanfar, N=24
747 observations). While F_{roh} distribution was similar for most cohorts, the Iranian cohort from
748 Sasanfar had a significantly lower mean than most other cohorts; **C:** grouped by country of

Biallelic variants for autism....



749 origin (Pakistan, N=55, Iran, N= 36, Saudi Arabia=13 observations). Comparison of mean F_{roh}
750 was non-significant for Pakistan versus Iran and versus Saudi Arabia, but significant for Iran
751 versus Saudi Arabia, but non-significant after correction for multiple testing ($p=0.0206$, $t=2.396$,
752 $d.f.=36$). Plots were prepared using R software using ggplot2, and show mean, standard
753 deviation, and outliers marked by “X”.

754


Biallelic variants for autism....



Biallelic variants for autism....



B



C

